News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
705,474 Results
Type
Article (40091)
Company Profile (257)
Press Release (665125)
Multimedia
Podcasts (59)
Webinars (14)
Section
Business (204474)
Career Advice (2015)
Deals (35480)
Drug Delivery (95)
Drug Development (81229)
Employer Resources (172)
FDA (16258)
Job Trends (14903)
News (345819)
Policy (32628)
Tag
Academia (2557)
Accelerated approval (9)
Adcomms (23)
Allergies (95)
Alliances (49640)
ALS (109)
Alzheimer's disease (1441)
Antibody-drug conjugate (ADC) (155)
Approvals (16251)
Artificial intelligence (309)
Autoimmune disease (28)
Automation (18)
Bankruptcy (361)
Best Places to Work (11645)
BIOSECURE Act (19)
Biosimilars (121)
Biotechnology (182)
Bladder cancer (93)
Brain cancer (33)
Breast cancer (365)
Cancer (2865)
Cardiovascular disease (212)
Career advice (1683)
Career pathing (30)
CAR-T (186)
CDC (30)
Cell therapy (498)
Cervical cancer (22)
Clinical research (66915)
Collaboration (1015)
Company closure (3)
Compensation (686)
Complete response letters (22)
COVID-19 (2630)
CRISPR (56)
C-suite (324)
Cystic fibrosis (112)
Data (2992)
Decentralized trials (2)
Denatured (20)
Depression (60)
Diabetes (346)
Diagnostics (6426)
Digital health (23)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (137)
Drug pricing (121)
Drug shortages (28)
Duchenne muscular dystrophy (124)
Earnings (87474)
Editorial (40)
Employer branding (21)
Employer resources (148)
Events (113887)
Executive appointments (845)
FDA (17902)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (932)
Gene editing (129)
Generative AI (22)
Gene therapy (375)
GLP-1 (780)
Government (4502)
Grass and pollen (4)
Guidances (181)
Healthcare (18855)
HIV (40)
Huntington's disease (30)
IgA nephropathy (39)
Immunology and inflammation (147)
Immuno-oncology (8)
Indications (39)
Infectious disease (2802)
Inflammatory bowel disease (149)
Inflation Reduction Act (10)
Influenza (62)
Intellectual property (119)
Interviews (313)
IPO (16602)
IRA (44)
Job creations (3646)
Job search strategy (1426)
Kidney cancer (13)
Labor market (52)
Layoffs (493)
Leadership (18)
Legal (7931)
Liver cancer (79)
Longevity (11)
Lung cancer (399)
Lymphoma (209)
Machine learning (11)
Management (58)
Manufacturing (383)
MASH (90)
Medical device (13464)
Medtech (13469)
Mergers & acquisitions (19592)
Metabolic disorders (847)
Multiple sclerosis (97)
NASH (16)
Neurodegenerative disease (114)
Neuropsychiatric disorders (32)
Neuroscience (2117)
NextGen: Class of 2025 (6528)
Non-profit (4489)
Now hiring (47)
Obesity (427)
Opinion (217)
Ovarian cancer (102)
Pain (106)
Pancreatic cancer (120)
Parkinson's disease (186)
Partnered (22)
Patents (296)
Patient recruitment (163)
Peanut (50)
People (57757)
Pharmaceutical (63)
Pharmacy benefit managers (21)
Phase I (20860)
Phase II (29477)
Phase III (21930)
Pipeline (1628)
Policy (200)
Postmarket research (2564)
Preclinical (8883)
Press Release (64)
Prostate cancer (140)
Psychedelics (36)
Radiopharmaceuticals (253)
Rare diseases (459)
Real estate (5930)
Recruiting (66)
Regulatory (22649)
Reports (50)
Research institute (2327)
Resumes & cover letters (351)
Rett syndrome (9)
RNA editing (8)
RSV (49)
Schizophrenia (86)
Series A (157)
Series B (109)
Service/supplier (11)
Sickle cell disease (60)
Special edition (18)
Spinal muscular atrophy (148)
Sponsored (32)
Startups (3594)
State (2)
Stomach cancer (14)
Supply chain (76)
Tariffs (57)
The Weekly (37)
Vaccines (778)
Venture capital (53)
Weight loss (256)
Women's health (47)
Worklife (16)
Date
Today (66)
Last 7 days (361)
Last 30 days (1885)
Last 365 days (31246)
2025 (16761)
2024 (35253)
2023 (40104)
2022 (51230)
2021 (55762)
2020 (54123)
2019 (46565)
2018 (35041)
2017 (32144)
2016 (31522)
2015 (37590)
2014 (31361)
2013 (26382)
2012 (28585)
2011 (29284)
2010 (27353)
Location
Africa (720)
Alabama (61)
Alaska (7)
Arizona (243)
Arkansas (13)
Asia (38282)
Australia (6255)
California (7439)
Canada (2361)
China (670)
Colorado (321)
Connecticut (318)
Delaware (193)
Europe (82239)
Florida (1116)
Georgia (247)
Hawaii (1)
Idaho (59)
Illinois (636)
India (26)
Indiana (361)
Iowa (16)
Japan (227)
Kansas (108)
Kentucky (29)
Louisiana (14)
Maine (64)
Maryland (1025)
Massachusetts (5524)
Michigan (246)
Minnesota (451)
Mississippi (3)
Missouri (90)
Montana (28)
Nebraska (25)
Nevada (80)
New Hampshire (66)
New Jersey (2070)
New Mexico (28)
New York (2082)
North Carolina (1082)
North Dakota (8)
Northern California (3275)
Ohio (235)
Oklahoma (16)
Oregon (34)
Pennsylvania (1624)
Puerto Rico (17)
Rhode Island (36)
South America (1098)
South Carolina (34)
South Dakota (1)
Southern California (2779)
Tennessee (126)
Texas (1124)
United States (27567)
Utah (219)
Virginia (184)
Washington D.C. (72)
Washington State (632)
West Virginia (4)
Wisconsin (66)
705,474 Results for "sillajen biotherapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Developing Precision Genetic Medicine Platform for Cancer Treatment
July 9, 2025
·
3 min read
Drug Development
SillaJen Submits CSR to the US FDA for REN026 Study in Patients with RCC
SillaJen, Inc. (KOSDAQ: 215600) has submitted CSR to the US FDA on 06 Feb 2024 for REN026, a phase 1b/2a dose escalation and safety/efficacy evaluation study of Pexa-Vec in combination with cemiplimab in patients with metastatic or unresectable renal cell carcinoma (RCC).
March 27, 2024
·
5 min read
Press Releases
Parataxis Holdings LLC Announces Definitive Agreement with Bridge Biotherapeutics, Inc. (KOSDAQ: 288330), to Bring Institutionally-Backed, Bitcoin Treasury Company to the South Korean Public Markets:
June 20, 2025
·
4 min read
Press Releases
Calidi Biotherapeutics Announces Shareholder Letter from CEO
June 27, 2025
·
6 min read
Press Releases
Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel®)
July 15, 2025
·
7 min read
Press Releases
Calidi Biotherapeutics Announces Exercise of Warrants for $4.6 Million of Gross Proceeds
July 10, 2025
·
5 min read
Antibody-drug conjugate (ADC)
Roche Ups ADC Bet With $1B in Biobucks for Oxford BioTherapeutics
Roche’s up to $1 billion investment will provide access to Oxford BioTherapeutics’ antibody-drug conjugate platform for undisclosed cancer targets.
March 19, 2025
·
1 min read
·
Tristan Manalac
Press Releases
Artiva Biotherapeutics to Participate in the 2025 Jefferies Global Healthcare Conference
May 29, 2025
·
3 min read
Press Releases
Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc.
February 12, 2025
·
6 min read
Press Releases
Chair of Sernova Biotherapeutics Resigns
May 26, 2025
·
1 min read
1 of 70,548
Next
